Ketamine and Esketamine for Treatment-Resistant Depression

Approximately 30% of patients with major depressive disorder do not find relief with traditional antidepressant treatments, leading to a condition known as treatment-resistant depression (TRD). Ketamine and esketamine have shown promise as rapid treatment modalities for TRD. This project aims to examine ketamine and esketamine's efficacy for TRD along with the mechanisms of action, safety/side effects, clinical application for TRD, legal considerations, research on ketamine and esketamine in relation to TRD, and research gaps.